Lyell Immunopharma (LYEL) Non-Current Deffered Revenue (2020 - 2022)

Lyell Immunopharma has reported Non-Current Deffered Revenue for 3 years, with the latest figure at $37.2 million in Q3 2022.

• Quarterly Non-Current Deffered Revenue fell 54.61% year-over-year to $37.2 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $37.2 million (down 54.61% YoY) and the FY2021 annual result came in at $79.7 million, down 10.56% from the prior year.
• Non-Current Deffered Revenue grew to $37.2 million in Q3 2022 per LYEL's latest filing, from $32.9 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $89.1 million in Q4 2020 and troughed at $32.9 million in Q2 2022.
• A 3-year average of $68.6 million and a median of $79.7 million in 2021 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2021 and 2022: Non-Current Deffered Revenue fell 10.56% in 2021, then sank 59.79% in 2022.
• Over 3 years, Non-Current Deffered Revenue stood at $89.1 million in 2020, then declined by 10.56% to $79.7 million in 2021, then plunged by 53.35% to $37.2 million in 2022.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $37.2 million, $32.9 million, and $77.9 million for Q3 2022, Q2 2022, and Q1 2022 respectively.